Cure: short‐term success · patients on maintenance HD with CRBSI
It is very uncertain whether systemic antibiotics plus antibiotic lock solutions plus tissue… changes cure: short‐term success compared with systemic antibiotics plus antibiotic lock solutions plus heparin (very low certainty).
1 finding from 1 review
RR 0.92 [0.74, 1.15]
18 participants
Very low
Cure: long‐term success · patients on maintenance HD with CRBSI
It is very uncertain whether systemic antibiotics plus antibiotic lock solutions plus tissue… changes cure: long‐term success compared with systemic antibiotics plus antibiotic lock solutions plus heparin (very low certainty).
1 finding from 1 review
RR 64 [0.38, 1.06]
18 participants
Very low
Cure: infection‐free survival · patients on maintenance HD with CRBSI
1 finding from 1 review
no estimate extracted
18 participants
Very low
Stenosis or thrombosis of vascular access site after catheter removal · patients on maintenance HD with CRBSI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients on maintenance HD with CRBSI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of antibiotic resistance · patients on maintenance HD with CRBSI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · patients on maintenance HD with CRBSI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from all causes (duration of · patients with acute pulmonary embolism
Thrombolytic therapy may leads to lower death from all causes (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Recurrence of pulmonary emboli · patients with acute pulmonary embolism
Thrombolytic therapy may leads to lower recurrence of pulmonary emboli (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Major bleeding · patients with acute pulmonary embolism
Thrombolytic therapy probably leads to higher major haemorrhagic events (duration of compared with heparin: primary outcome measures (moderate certainty).
1 finding from 1 review
Minor haemorrhagic events (duration of · patients with acute pulmonary embolism
Thrombolytic therapy may leads to higher minor haemorrhagic events (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
All‐cause mortality · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in mortality compared with heparin (low certainty).
1 finding from 1 review
Recurrent VTE · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in recurrent VTE compared with heparin (low certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in major bleeding compared with heparin (low certainty).
1 finding from 1 review
Minor bleeding · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in minor bleeding compared with heparin (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postphlebitic syndrome ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review